By Dr Lynn Butler The barriers to establishing an equitable partnership between biotechs and big pharma are high and many partnerships, once established, do not deliver the tangible and non-tangible value expected by the licensor. This article addresses how to develop and implement a partnering strategy that will deliver attractive value, avoid the erosion of [...]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!